Anti-IgE Antibodies for the Treatment of IgE-Mediated Allergic Diseases

Advances in Immunology

Volumn 93, Issue , 2007, Pages 63-119

  Chang, Tse Wen ^a   Wu, Pheidias C ^a,b   Hsu, C Long ^a,b   Hung, Alfur F ^a,b  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CGP 51901; CORTICOSTEROID; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOMODULATING AGENT; LATEX; MONOCLONAL ANTIBODY; OMALIZUMAB; PEPTIDE ANTIBODY; PLACEBO; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADJUVANT THERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIGEN ANTIBODY COMPLEX; ATOPIC DERMATITIS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; DOSE RESPONSE; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ECZEMA; ENVENOMATION; ENVIRONMENTAL FACTOR; EYE ALLERGY; FEVER; FOOD ALLERGY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOTHERAPY; INJECTION SITE RASH; LONG TERM CARE; MAST CELL; MONOTHERAPY; NONHUMAN; NOSE ALLERGY; PATHOGENESIS; PEANUT ALLERGY; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; REMISSION; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; URTICARIA;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY;

EID: 33947307347     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(06)93002-8     Document Type: Review

References (234)

1. Adelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., Byrne A., Champain K., Thirlwell J., Cioppa G.D., and Sandstrom T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 106 (2000) 253-259
2. Ames S.A., Gleeson C.D., and Kirkpatrick P. Omalizumab. Nat. Rev. Drug. Discov. 3 (2004) 199-200
3. Amiri P., Haak-Frendscho M., Robbins K., McKerrow J.H., Stewart T., and Jardieu P. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J. Exp. Med. 180 (1994) 43-51
4. Asai K., Kitaura J., Kawakami Y., Yamagata N., Tsai M., Carbone D.P., Liu F.T., Galli S.J., and Kawakami T. Regulation of mast cell survival by IgE. Immunity 14 (2001) 791-800
5. Asher M.I., Montefort S., Bjorksten B., Lai C.K., Strachan D.P., Weiland S.K., and Williams H. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368 (2006) 733-743
6. Aubry J.P., Pochon S., Graber P., Jansen K.U., and Bonnefoy J.Y. CD21 is a ligand for CD23 and regulates IgE production. Nature 358 (1992) 505-507
7. Ayres J.G., Higgins B., Chilvers E.R., Ayre G., Blogg M., and Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59 (2004) 701-708
8. Barnes P.J. Cytokine modulators as novel therapies for asthma. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 81-98
9. Barnes P.J. New drugs for asthma. Nat. Rev. Drug Discov. 3 (2004) 831-844
10. Baur X. Studies on the specificity of human IgE-antibodies to the plant proteases papain and bromelain. Clin. Allergy 9 (1979) 451-457
11. Beck L.A., and Leung D.Y. Allergen sensitization through the skin induces systemic allergic responses. J. Allergy Clin. Immunol. 106 (2000) S258-S263
12. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J. Allergy Clin. Immunol. 114 (2004) 527-530
13. Berger W., Gupta N., McAlary M., and Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann. Allergy Asthma Immunol. 91 (2003) 182-188
14. Bernstein D.I. Allergic reactions to workplace allergens. JAMA 278 (1997) 1907-1913
15. Bernstein D.I., Wanner M., Borish L., and Liss G.M. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 113 (2004) 1129-1136
16. Bez C., Schubert R., Kopp M., Ersfeld Y., Rosewich M., Kuehr J., Kamin W., Berg A.V., Wahu U., and Zielen S. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin. Exp. Allergy 34 (2004) 1079-1085
17. Bich-Thuy L.T., Banchereau J., and Revillard J.P. Suppression of polyclonal human B cell activation by IgG binding factors: Interference with the maturation of Ig-containing cells into Ig-secreting cells. Cell. Immunol. 87 (1984) 231-239
18. Bingham III C.O., and Austen K.F. Mast-cell responses in the development of asthma. J. Allergy Clin. Immunol. 105 (2000) S527-S534
19. Bodtger U., Poulsen L.K., and Linneberg A. Rhinitis symptoms and IgE sensitization as risk factors for development of later allergic rhinitis in adults. Allergy 61 (2006) 712-716
20. Borchers A.T., Keen C.L., and Gershwin M.E. Fatalities following allergen immunotherapy. Clin. Rev. Allergy Immunol. 27 (2004) 147-158
21. Borish L., Chipps B., Deniz Y., Gujrathi S., Zheng B., and Dolan C.M. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann. Allergy Asthma Immunol. 95 (2005) 247-253
22. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., and Agosti J.M. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107 (2001) 963-970
23. Borkowski T.A., Jouvin M.H., Lin S.Y., and Kinet J.P. Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J. Immunol. 167 (2001) 1290-1296
24. Boulet L.P., Turcotte H., Laprise C., Lavertu C., Bedard P.M., Lavoie A., and Hebert J. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Clin. Exp. Allergy 27 (1997) 52-59
25. Bousquet J., Becker W.M., Hejjaoui A., Chanal I., Lebel B., Dhivert H., and Michel F.B. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J. Allergy Clin. Immunol. 88 (1991) 43-53
26. Bousquet J., Wenzel S., Holgate S., Lumry W., Freeman P., and Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 125 (2004) 1378-1386
27. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., Fox H., Hedgecock S., Blogg M., and Cioppa G.D. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60 (2005) 302-308
28. Boyce J.A. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J. Allergy Clin. Immunol. 117 (2006) 1415-1418
29. Braunstahl G.J. The unified immune system: Respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J. Allergy Clin. Immunol. 115 (2005) 142-148
30. Brody D., and Metcalfe D.D. Mast cells: A unique and functional diversity. Clin. Exp. Allergy 28 (1998) 1167-1170
31. Buhl R., Hanf G., Soler M., Bensch G., Wolfe J., Everhard F., Champain K., Fox H., and Thirlwell J. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J. 20 (2002) 1088-1094
32. Burrows B., Martinez F.D., Halonen M., Barbee R.A., and Cline M.G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. 320 (1989) 271-277
33. Busse W.W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am. J. Respir. Crit. Care Med. 164 (2001) S12-S17
34. Capron A., and Dessaint J.P. Immunologic aspects of schistosomiasis. Annu. Rev. Med. 43 (1992) 209-218
35. Capron M., and Capron A. Immunoglobulin E and effector cells in schistosomiasis. Science 264 (1994) 1876-1877
36. Capron A., Dessaint J.P., Capron M., Ouma J.H., and Butterworth A.E. Immunity to schistosomes: Progress toward vaccine. Science 238 (1987) 1065-1072
37. Caraux J., and Weigle W.O. Anti-idiotype antibody-dependent cell-mediated cytotoxicity (ADCC) against idiotype-bearing cells. Cell. Immunol. 78 (1983) 23-32
38. Caraux J., and Weigle W.O. Surface immunoglobulins as targets for anti-immunoglobulin-dependent cell-mediated lysis of B cells. Cell. Immunol. 76 (1983) 372-378
39. Carlsen K.H. Therapeutic strategies for allergic airways diseases. Paediatr. Respir. Rev. 5 (2004) 45-51
40. Casale T.B. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. Am. J. Respir. Crit. Care Med. 164 (2001) S18-S21
41. Casale T.B., Bernstein I.L., Busse W.W., LaForce C.F., Tinkelman D.G., Stoltz R.R., Dockhorn R.J., Reimann J., Su J.Q., Fick Jr. R.B., and Adelman D.C. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 100 (1997) 110-121
42. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., McAlary M., Fowler-Taylor A., Racine A., Gupta N., Fick R., and Della Cioppa G. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 286 (2001) 2956-2967
43. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., Mokhtarani M., Seyfert-Margolis V., Asare A., Bateman K., and Deniz Y. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 117 (2006) 134-140
44. Chan C.S., Soehnlen F., and Schechter G.P. Differential response of malignant human B-cells to anti-IgM immunoglobulin (anti-mu) and B-cell growth factor: Unique direct cytotoxicity of anti-mu on prolymphocytic leukemia cells. Blood 76 (1990) 1601-1606
45. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 18 (2000) 157-162
46. Chang T.W. Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E. Allergy Asthma Proc. 27 (2006) S7-S14
47. Chang T.W., and Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J. Allergy Clin. Immunol. 117 (2006) 1203-1212
48. Chang T.W., Kung P.C., Gingras S.P., and Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?. Proc. Natl. Acad. Sci. USA 78 (1981) 1805-1808
49. Chang T.W., Davis F.M., Sun N.C., Sun C.R., MacGlashan Jr. D.W., and Hamilton R.G. Monoclonal antibodies specific for human IgE-producing B cells: A potential therapeutic for IgE-mediated allergic diseases. Biotechnology (NY) 8 (1990) 122-126
50. Chen H.Y., Liu F.T., Hou C.M., Huang J.S., Sharma B.B., and Chang T.W. Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells. Int. Arch. Allergy Immunol. 128 (2002) 315-324
51. Church M.K., and Levi-Schaffer F. The human mast cell. J. Allergy Clin. Immunol. 99 (1997) 155-160
52. Coker H.A., Durham S.R., and Gould H.J. Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J. Immunol. 171 (2003) 5602-5610
53. Conroy M.C., Adkinson Jr. N.F., and Lichtenstein L.M. Measurement of IgE on human basophils: Relation to serum IgE and anti-IgE-induced histamine release. J. Immunol. 118 (1977) 1317-1321
54. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 402 (1999) B5-B11
55. Corne J., Djukanovic R., Thomas L., Warner J., Botta L., Grandordy B., Gygax D., Heusser C., Patalano F., Richardson W., Kilchherr E., Staehelin T., et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J. Clin. Invest. 99 (1997) 879-887
56. Davis F.M., Gossett L.A., Pinkston K.L., Liou R.S., Sun L.K., Kim Y.W., Chang N.T., Chang T.W., Wagner K., Bews J., Brinkmann V., Towbin H., et al. Can anti-IgE be used to treat allergy?. Springer Semin. Immunopathol. 15 (1993) 51-73
57. DeFranco A.L. Structure and function of the B cell antigen receptor. Annu. Rev. Cell Biol. 9 (1993) 377-410
58. de Vries J.E., Punnonen J., Cocks B.G., de Waal Malefyt R., and Aversa G. Regulation of the human IgE response by IL4 and IL13. Res. Immunol. 144 (1993) 597-601
59. Donjerkovic D., and Scott D.W. Activation-induced cell death in B lymphocytes. Cell Res. 10 (2000) 179-192
60. Dreyfus D.H., and Randolph C.C. Characterization of an anaphylactoid reaction to omalizumab. Ann. Allergy Asthma Immunol. 96 (2006) 624-627
61. Ebo D.G., and Stevens W.J. IgE-mediated natural rubber latex allergy: Practical considerations for health care workers. Ann. Allergy Asthma Immunol. 88 (2002) 568-575
62. Edwards A.M. The discovery of cromolyn sodium and its effect on research and practice in allergy and immunology. J. Allergy Clin. Immunol. 115 (2005) 885-888
63. Eigenmann P.A., Sicherer S.H., Borkowski T.A., Cohen B.A., and Sampson H.A. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 101 (1998) 8-13
64. El Ridi R., Ozaki T., and Kamiya H. Schistosoma mansoni infection in IgE-producing and IgE-deficient mice. J. Parasitol. 84 (1998) 171-174
65. Fahy J.V., Fleming H.E., Wong H.H., Liu J.T., Su J.Q., Reimann J., Fick Jr. R.B., and Boushey H.A. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155 (1997) 1828-1834
66. Finn A., Gross G., van Bavel J., Lee T., Windom H., Everhard F., Fowler-Taylor A., Liu J., and Gupta N. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 111 (2003) 278-284
67. Fish J.E. Occupational asthma and rhinoconjunctivitis induced by natural rubber latex exposure. J. Allergy Clin. Immunol. 110 (2002) S75-S81
68. Fodinger M., Fritsch G., Winkler K., Emminger W., Mitterbauer G., Gadner H., Valent P., and Mannhalter C. Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84 (1994) 2954-2959
69. Foote J. Immunology. Isomeric antibodies. Science 299 (2003) 1327-1328
70. Fox J.A., Hotaling T.E., Struble C., Ruppel J., Bates D.J., and Schoenhoff M.B. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 279 (1996) 1000-1008
71. Galli S.J., and Hammel I. Mast cell and basophil development. Curr. Opin. Hematol. 1 (1994) 33-39
72. Garman S.C., Kinet J.P., and Jardetzky T.S. Crystal structure of the human high-affinity IgE receptor. Cell 95 (1998) 951-961
73. Garman S.C., Wurzburg B.A., Tarchevskaya S.S., Kinet J.P., and Jardetzky T.S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 406 (2000) 259-266
74. Gauld S.B., Benschop R.J., Merrell K.T., and Cambier J.C. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 6 (2005) 1160-1167
75. Getahun A., Hjelm F., and Heyman B. IgE enhances antibody and T cell responses in vivo via CD23+ B cells. J. Immunol. 175 (2005) 1473-1482
76. Gold D.R., and Wright R. Population disparities in asthma. Annu. Rev. Public Health 26 (2005) 89-113
77. Gould H.J., Sutton B.J., Beavil A.J., Beavil R.L., McCloskey N., Coker H.A., Fear D., and Smurthwaite L. The biology of IGE and the basis of allergic disease. Annu. Rev. Immunol. 21 (2003) 579-628
78. Greineder D.K. Risk management in allergen immunotherapy. J. Allergy Clin. Immunol. 98 (1996) S330-S334
79. Gurish M.F., Bryce P.J., Tao H., Kisselgof A.B., Thornton E.M., Miller H.R., Friend D.S., and Oettgen H.C. IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella spiralis. J. Immunol. 172 (2004) 1139-1145
80. Haak-Frendscho M., Robbins K., Lyon R., Shields R., Hooley J., Schoenhoff M., and Jardieu P. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 82 (1994) 306-313
81. Haba S., and Nisonoff A. Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc. Natl. Acad. Sci. USA 87 (1990) 3363-3367
82. Haba S., and Nisonoff A. Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J. Immunol. 152 (1994) 51-57
83. Hamelmann E., Oshiba A., Schwarze J., Bradley K., Loader J., Larsen G.L., and Gelfand E.W. Allergen-specific IgE and IL-5 are essential for the development of airway hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 16 (1997) 674-682
84. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P., and Cook R.M. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130 (2002) 93-100
85. Heaney L.G., and Robinson D.S. Severe asthma treatment: Need for characterising patients. Lancet 365 (2005) 974-976
86. Hibbert R.G., Teriete P., Grundy G.J., Beavil R.L., Reljic R., Holers V.M., Hannan J.P., Sutton B.J., Gould H.J., and McDonnell J.M. The structure of human CD23 and its interactions with IgE and CD21. J. Exp. Med. 202 (2005) 751-760
87. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., and Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 115 (2005) 459-465
88. Holgate S.T., Djukanovic R., Casale T., and Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: An update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 35 (2005) 408-416
89. Hoover R.G., and Lynch R.G. Isotype-specific suppression of IgA: Suppression of IgA responses in BALB/c mice by T alpha cells. J. Immunol. 130 (1983) 521-523
90. Hoskins G., McCowan C., Neville R.G., Thomas G.E., Smith B., and Silverman S. Risk factors and costs associated with an asthma attack. Thorax 55 (2000) 19-24
91. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., Beeh K.M., Ramos S., Canonica G.W., Hedgecock S., Fox H., Blogg M., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005) 309-316
92. Infuhr D., Crameri R., Lamers R., and Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy 60 (2005) 977-985
93. Irani A.M., and Schwartz L.B. Human mast cell heterogeneity. Allergy Proc. 15 (1994) 303-308
94. Ishizaka K., and Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J. Immunol. 99 (1967) 1187-1198
95. Ishizaka T., Conrad D.H., Schulman E.S., Sterk A.R., Ko C.G., and Ishizaka K. IgE-mediated triggering signals for mediator release from human mast cells and basophils. Fed. Proc. 43 (1984) 2840-2845
96. Isolauri E., Huurre A., Salminen S., and Impivaara O. The allergy epidemic extends beyond the past few decades. Clin. Exp. Allergy 34 (2004) 1007-1010
97. James L.C., Roversi P., and Tawfik D.S. Antibody multispecificity mediated by conformational diversity. Science 299 (2003) 1362-1367
98. Janeway Jr. C.A., Travers P., Walport M., and Shlomchik M.J. "Immunobiology: The Immune System in Health and Disease." (2005), Garland Science Publishing, New York
99. Jankovic D., Kullberg M.C., Dombrowicz D., Barbieri S., Caspar P., Wynn T.A., Paul W.E., Cheever A.W., Kinet J.P., and Sher A. Fc epsilonRI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology. J. Immunol. 159 (1997) 1868-1875
100. Johansson S.G. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 2 (1967) 951-953
101. Kalesnikoff J., Huber M., Lam V., Damen J.E., Zhang J., Siraganian R.P., and Krystal G. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 14 (2001) 801-811
102. Kasaian M.T., Meyer C.H., Nault A.K., and Bond J.F. An increased frequency of IgE-producing B cell precursors contributes to the elevated levels of plasma IgE in atopic subjects. Clin. Exp. Allergy 25 (1995) 749-755
103. Kawakami T., and Galli S.J. Regulation of mast-cell and basophil function and survival by IgE. Nat. Rev. Immunol. 2 (2002) 773-786
104. Kawakami T., and Kitaura J. Mast cell survival and activation by IgE in the absence of antigen: A consideration of the biologic mechanisms and relevance. J. Immunol. 175 (2005) 4167-4173
105. Keown M.B., Ghirlando R., Mackay G.A., Sutton B.J., and Gould H.J. Basis of the 1:1 stoichiometry of the high affinity receptor Fc epsilon RI-IgE complex. Eur. Biophys. J. 25 (1997) 471-476
106. Kilmon M.A., Shelburne A.E., Chan-Li Y., Holmes K.L., and Conrad D.H. CD23 trimers are preassociated on the cell surface even in the absence of its ligand, IgE. J. Immunol. 172 (2004) 1065-1073
107. Kinet J.P. The high-affinity IgE receptor (Fc epsilon RI): From physiology to pathology. Annu. Rev. Immunol. 17 (1999) 931-972
108. King C.L., Xianli J., Malhotra I., Liu S., Mahmoud A.A., and Oettgen H.C. Mice with a targeted deletion of the IgE gene have increased worm burdens and reduced granulomatous inflammation following primary infection with Schistosoma mansoni. J. Immunol. 158 (1997) 294-300
109. King T.P., and Spangfort M.D. Structure and biology of stinging insect venom allergens. Int. Arch. Allergy Immunol. 123 (2000) 99-106
110. Kips J.C., Tournoy K.G., and Pauwels R.A. New anti-asthma therapies: Suppression of the effect of interleukin (IL)-4 and IL-5. Eur. Respir. J. 17 (2001) 499-506
111. Kitaura J., Song J., Tsai M., Asai K., Maeda-Yamamoto M., Mocsai A., Kawakami Y., Liu F.T., Lowell C.A., Barisas B.G., Galli S.J., and Kawakami T. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc. Natl. Acad. Sci. USA 100 (2003) 12911-12916
112. Kitaura J., Kinoshita T., Matsumoto M., Chung S., Kawakami Y., Leitges M., Wu D., Lowell C.A., and Kawakami T. IgE- and IgE+ Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood 105 (2005) 3222-3229
113. KleinJan A., Vinke J.G., Severijnen L.W., and Fokkens W.J. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur. Respir. J. 15 (2000) 491-497
114. Kohno M., Yamasaki S., Tybulewicz V.L., and Saito T. Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 105 (2005) 2059-2065
115. Kolbinger F., Saldanha J., Hardman N., and Bendig M.M. Humanization of a mouse anti-human IgE antibody: A potential therapeutic for IgE-mediated allergies. Protein Eng. 6 (1993) 971-980
116. Kopp M.V., Mayatepek E., Engels E., Brauburger J., Riedinger F., Ihorst G., Wahn U., and Kuehr J. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). Pediatr. Allergy Immunol. 14 (2003) 401-404
117. Kraft S., Katoh N., Novak N., Koch S., and Bieber T. Unexpected functions of FcepsilonRI on antigen-presenting cells. Int. Arch. Allergy Immunol. 124 (2001) 35-37
118. Krathen R.A., and Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J. Am. Acad. Dermatol. 53 (2005) 338-340
119. Kubo S., Matsuoka K., Taya C., Kitamura F., Takai T., Yonekawa H., and Karasuyama H. Drastic up-regulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface. J. Immunol. 167 (2001) 3427-3434
120. Kuehr J., Brauburger J., Zielen S., Schauer U., Kamin W., Von Berg A., Leupold W., Bergmann K.C., Rolinck-Werninghaus C., Grave M., Hultsch T., and Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109 (2002) 274-280
121. Kussin P.S., and Fulkerson W.J. The rising tide of asthma. Trends in the epidemiology of morbidity and mortality from asthma. Respir. Care Clin. North Am. 1 (1995) 163-175
122. Lam V., Kalesnikoff J., Lee C.W., Hernandez-Hansen V., Wilson B.S., Oliver J.M., and Krystal G. IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE+ antigen but distinct from those used by Steel factor. Blood 102 (2003) 1405-1413
123. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., and Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J. Am. Acad. Dermatol. 54 (2006) 68-72
124. Lanier B. Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc. 27 (2006) S37-S42
125. Lanier B.Q. Newer aspects in the treatment of pediatric and adult asthma: Monoclonal anti-IgE. Ann. Allergy Asthma Immunol. 90 (2003) 13-15
126. Lanier B.Q., and Chang T.W. Will anti-IgE therapy compromise normal immune functions?. Allergy Clin. Immunol. Int.: J. World Allergy Org. 16 (2004) 237-240
127. Lanier B.Q., Corren J., Lumry W., Liu J., Fowler-Taylor A., and Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol. 91 (2003) 154-159
128. Laske N., Bunikowski R., and Niggemann B. Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Ann. Allergy Asthma Immunol. 91 (2003) 202-204
129. Lee J., Doggweiler-Wiygul R., Kim S., Hill B.D., and Yoo T.J. Is interstitial cystitis an allergic disorder? A case of interstitial cystitis treated successfully with anti-IgE. Int. J. Urol. 13 (2006) 631-634
130. Lemanske Jr. R.F., Nayak A., McAlary M., Everhard F., Fowler-Taylor A., and Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110 (2002) 55-59
131. Lemiere C., Cartier A., Dolovich J., and Malo J.L. Isolated late asthmatic reaction after exposure to a high-molecular-weight occupational agent, subtilisin. Chest 110 (1996) 823-824
132. Leung D.Y. Role of IgE in atopic dermatitis. Curr. Opin. Immunol. 5 (1993) 956-962
133. Leung D.Y., and Soter N.A. Cellular and immunologic mechanisms in atopic dermatitis. J. Am. Acad. Dermatol. 44 (2001) S1-S12
134. Leung D.Y., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., Davis F.M., Hyun J.D., and Shanahan Jr. W.R. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 348 (2003) 986-993
135. Lewis R.A., and Austen K.F. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature 293 (1981) 103-108
136. Leynadier F., Doudou O., Gaouar H., Le Gros V., Bourdeix I., Guyomarch-Cocco L., and Trunet P. Effect of omalizumab in health care workers with occupational latex allergy. J. Allergy Clin. Immunol. 113 (2004) 360-361
137. Leynaert B., Bousquet J., Neukirch C., Liard R., and Neukirch F. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: Results from the European Community Respiratory Health Survey. J. Allergy Clin. Immunol. 104 (1999) 301-304
138. Li H., Nowak-Wegrzyn A., Charlop-Powers Z., Shreffler W., Chehade M., Thomas S., Roda G., Dahan S., Sperber K., and Berin M.C. Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial cells and its role in food allergy. Gastroenterology 131 (2006) 47-58
139. Limb S.L., Brown K.C., Wood R.A., Eggleston P.A., Hamilton R.G., and Adkinson Jr. N.F. Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy. Int. Arch. Allergy Immunol. 140 (2006) 245-251
140. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., Townley R., and Casale T.B. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J. Allergy Clin. Immunol. 113 (2004) 297-302
141. Litman G.W., Cannon J.P., and Dishaw L.J. Reconstructing immune phylogeny: New perspectives. Nat. Rev. Immunol. 5 (2005) 866-879
142. Liu F.T. Truly MASTerful cells: Mast cells command B cell IgE synthesis. J. Clin. Invest. 99 (1997) 1465-1466
143. Liu J., Lester P., Builder S., and Shire S.J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34 (1995) 10474-10482
144. Lowman M.A., Rees P.H., Benyon R.C., and Church M.K. Human mast cell heterogeneity: Histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J. Allergy Clin. Immunol. 81 (1988) 590-597
145. MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J. Allergy Clin. Immunol. 114 (2004) 1472-1474
146. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., Sterbinsky S.A., Hamilton R.G., and Lichtenstein L.M. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158 (1997) 1438-1445
147. MacGlashan Jr. D., McKenzie-White J., Chichester K., Bochner B.S., Davis F.M., Schroeder J.T., and Lichtenstein L.M. In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 91 (1998) 1633-1643
148. MacGlashan Jr. D., Lichtenstein L.M., McKenzie-White J., Chichester K., Henry A.J., Sutton B.J., and Gould H.J. Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. J. Allergy Clin. Immunol. 104 (1999) 492-498
149. Madden K.B., Urban Jr. J.F., Ziltener H.J., Schrader J.W., Finkelman F.D., and Katona I.M. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J. Immunol. 147 (1991) 1387-1391
150. Maeyama K., Hohman R.J., Metzger H., and Beaven M.A. Quantitative relationships between aggregation of IgE receptors, generation of intracellular signals, and histamine secretion in rat basophilic leukemia (2H3) cells. Enhanced responses with heavy water. J. Biol. Chem. 261 (1986) 2583-2592
151. Malveaux F.J., Conroy M.C., Adkinson Jr. N.F., and Lichtenstein L.M. IgE receptors on human basophils. Relationship to serum IgE concentration. J. Clin. Invest. 62 (1978) 176-181
152. Manz R.A., Hauser A.E., Hiepe F., and Radbruch A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23 (2005) 367-386
153. Mayumi M., Sumimoto S., Kanazashi S., Hata D., Yamaoka K., Higaki Y., Ishigami T., Kim K.M., Heike T., and Katamura K. Negative signaling in B cells by surface immunoglobulins. J. Allergy Clin. Immunol. 98 (1996) S238-S247
154. Menz G., Ying S., Durham S.R., Corrigan C.J., Robinson D.S., Hamid Q., Pfister R., Humbert M., and Kay A.B. Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma. Allergy 53 (1998) 15-21
155. Metzger H., Goetze A., Kanellopoulos J., Holowka D., and Fewtrell C. Structure of the high-affinity mast cell receptor for IgE. Fed. Proc. 41 (1982) 8-11
156. Metzger H., Alcaraz G., Hohman R., Kinet J.P., Pribluda V., and Quarto R. The receptor with high affinity for immunoglobulin E. Annu. Rev. Immunol. 4 (1986) 419-470
157. Milgrom H. Anti-IgE therapy in children with asthma. Minerva Pediatr. 56 (2004) 469-479
158. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., Taylor A.F., and Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108 (2001) 36-45
159. Miller J.S., and Schwartz L.B. Human mast cell proteases and mast cell heterogeneity. Curr. Opin. Immunol. 1 (1989) 637-642
160. Mimura T., Amano S., Funatsu H., Yamagami S., Araie M., Kaji Y., Arimoto A., Ishida Y., Usui T., and Okamoto S. Correlations between allergen-specific IgE serum levels in patients with allergic conjunctivitis in spring. Ocul. Immunol. Inflamm. 12 (2004) 45-51
161. Nakamura T., Kloetzer W.S., Brams P., Hariharan K., Chamat S., Cao X., LaBarre M.J., Chinn P.C., Morena R.A., Shestowsky W.S., Li Y.P., Chen A., et al. In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. Int. J. Immunopharmacol. 22 (2000) 131-141
162. Nayak A., Casale T., Miller S.D., Condemi J., McAlary M., Fowler-Taylor A., Della Cioppa G., and Gupta N. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 24 (2003) 323-329
163. Nelson H.S. Advances in upper airway diseases and allergen immunotherapy. J. Allergy Clin. Immunol. 111 (2003) S793-S798
164. Niiro H., and Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2 (2002) 945-956
165. Noga O., Hanf G., and Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int. Arch. Allergy Immunol. 131 (2003) 46-52
166. Novak N., and Bieber T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 112 (2003) 252-262
167. Novak N., Bieber T., and Leung D.Y. Immune mechanisms leading to atopic dermatitis. J. Allergy Clin. Immunol. 112 (2003) S128-S139
168. Novak N., Kraft S., and Bieber T. Unraveling the mission of FcepsilonRI on antigen-presenting cells. J. Allergy Clin. Immunol. 111 (2003) 38-44
169. Oba Y., and Salzman G.A. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J. Allergy Clin. Immunol. 114 (2004) 265-269
170. Oettgen H.C., and Geha R.S. IgE in asthma and atopy: Cellular and molecular connections. J. Clin. Invest. 104 (1999) 829-835
171. Oettgen H.C., and Geha R.S. IgE regulation and roles in asthma pathogenesis. J. Allergy Clin. Immunol. 107 (2001) 429-440
172. Ong Y.E., Menzies-Gow A., Barkans J., Benyahia F., Ou T.T., Ying S., and Kay A.B. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J. Allergy Clin. Immunol. 116 (2005) 558-564
173. 2+, degranulation, and membrane ruffling in the cultured rat basophilic leukemia-2H3 mast cell line. J. Immunol. 172 (2004) 4048-4058
174. Parks K.W., and Casale T.B. Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc. 27 (2006) S33-S36
175. Pawankar R., Okuda M., Yssel H., Okumura K., and Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J. Clin. Invest. 99 (1997) 1492-1499
176. Peng C., Davis F.M., Sun L.K., Liou R.S., Kim Y.W., and Chang T.W. A new isoform of human membrane-bound IgE. J. Immunol. 148 (1992) 129-136
177. Peng Q., McEuen A.R., Benyon R.C., and Walls A.F. The heterogeneity of mast cell tryptase from human lung and skin. Eur. J. Biochem. 270 (2003) 270-283
178. Poole J.A., Meng J., Reff M., Spellman M.C., and Rosenwasser L.J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 116 (2005) 780-788
179. Posner R.G., Savage P.B., Peters A.S., Macias A., DelGado J., Zwartz G., Sklar L.A., and Hlavacek W.S. A quantitative approach for studying IgE-FcepsilonRI aggregation. Mol. Immunol. 38 (2002) 1221-1228
180. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., and Jardieu P.M. Humanization of an antibody directed against IgE. J. Immunol. 151 (1993) 2623-2632
181. Prickman L.E. Allergic asthma. Minn. Med. 34 (1951) 755-756
182. Pritchard D.I. Immunity to helminths: Is too much IgE parasite-rather than host-protective?. Parasite Immunol. 15 (1993) 5-9
183. Prussin C., Griffith D.T., Boesel K.M., Lin H., Foster B., and Casale T.B. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J. Allergy Clin. Immunol. 112 (2003) 1147-1154
184. Pruzansky J.J., and Patterson R. Limiting concentrations of human basophil-bound IgE antibody required for histamine release. Immunology 64 (1988) 307-310
185. Racine-Poon A., Botta L., Chang T.W., Davis F.M., Gygax D., Liou R.S., Rohane P., Staehelin T., van Steijn A.M., and Frank W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol. Ther. 62 (1997) 675-690
186. Razin E., Mencia-Huerta J.M., Stevens R.L., Lewis R.A., Liu F.T., Corey E., and Austen K.F. IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells. J. Exp. Med. 157 (1983) 189-201
187. Reljic R., Cosentino G., and Gould H.J. Function of CD23 in the response of human B cells to antigen. Eur. J. Immunol. 27 (1997) 572-575
188. Rolinck-Werninghaus C., Hamelmann E., Keil T., Kulig M., Koetz K., Gerstner B., Kuehr J., Zielen S., Schauer U., Kamin W., Von Berg A., Hammermann J., et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59 (2004) 973-979
189. Rosenwasser L.J., Busse W.W., Lizambri R.G., Olejnik T.A., and Totoritis M.C. Allergic asthma and an anti-CD23 mAb (IDEC-152): Results of a phase I, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 112 (2003) 563-570
190. Ross R.N., Nelson H.S., and Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: A meta-analysis. Clin. Ther. 22 (2000) 351-358
191. Sabra A., Bellanti J.A., Rais J.M., Castro H.J., de Inocencio J.M., and Sabra S. IgE and non-IgE food allergy. Ann. Allergy Asthma Immunol. 90 (2003) 71-76
192. Schafer T., and Przybilla B. IgE antibodies to Hymenoptera venoms in the serum are common in the general population and are related to indications of atopy. Allergy 51 (1996) 372-377
193. Schoenwetter W.F. Allergic rhinitis: Epidemiology and natural history. Allergy Asthma Proc. 21 (2000) 1-6
194. Serafin W.E., and Austen K.F. Mediators of immediate hypersensitivity reactions. N. Engl. J. Med. 317 (1987) 30-34
195. Shapiro-Shelef M., and Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol. 5 (2005) 230-242
196. Sharkey P., and Portnoy J. Rush immunotherapy: Experience with a one-day schedule. Ann. Allergy Asthma Immunol. 76 (1996) 175-180
197. Shehade S.A., Layton G.T., and Stanworth D.R. IgG4 and IgE antibodies in atopic dermatitis and urticaria. Clin. Exp. Dermatol. 13 (1988) 393-396
198. Sher A., Coffman R.L., Hieny S., and Cheever A.W. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J. Immunol. 145 (1990) 3911-3916
199. Sicherer S.H., and Leung D.Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects. J. Allergy Clin. Immunol. 116 (2005) 153-163
200. Skolnick H.S., Conover-Walker M.K., Koerner C.B., Sampson H.A., Burks W., and Wood R.A. The natural history of peanut allergy. J. Allergy Clin. Immunol. 107 (2001) 367-374
201. Smurthwaite L., Walker S.N., Wilson D.R., Birch D.S., Merrett T.G., Durham S.R., and Gould H.J. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur. J. Immunol. 31 (2001) 3422-3431
202. Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., Thirlwell J., Gupta N., and Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18 (2001) 254-261
203. Somos S., Schneider I., and Farkas B. Immunoglobulins in tears and sera in patients with atopic dermatitis. Allergy Asthma Proc. 22 (2001) 81-86
204. Stokes J., and Casale T.B. Rationale for new treatments aimed at IgE immunomodulation. Ann. Allergy Asthma Immunol. 93 (2004) 212-217
205. Storms W., and Kaliner M.A. Cromolyn sodium: Fitting an old friend into current asthma treatment. J. Asthma 42 (2005) 79-89
206. Strunk R.C., and Bloomberg G.R. Omalizumab for asthma. N. Engl. J. Med. 354 (2006) 2689-2695
207. Sun L.K., Liou R.S., Sun N.C., Gossett L.A., Sun C., Davis F.M., MacGlashan Jr. D.W., and Chang T.W. Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity. J. Immunol. 146 (1991) 199-205
208. Sussman G.L., Beezhold D.H., and Kurup V.P. Allergens and natural rubber proteins. J. Allergy Clin. Immunol. 110 (2002) S33-S39
209. Takhar P., Smurthwaite L., Coker H.A., Fear D.J., Banfield G.K., Carr V.A., Durham S.R., and Gould H.J. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J. Immunol. 174 (2005) 5024-5032
210. Tanaka S., Takasu Y., Mikura S., Satoh N., and Ichikawa A. Antigen-independent induction of histamine synthesis by immunoglobulin E in mouse bone marrow-derived mast cells. J. Exp. Med. 196 (2002) 229-235
211. 2+ influx-mediated histamine synthesis and IL-6 release in mast cells activated by monomeric IgE. Eur. J. Immunol. 35 (2005) 460-468
212. Tighe H., Warnatz K., Brinson D., Corr M., Weigle W.O., Baird S.M., and Carson D.A. Peripheral deletion of rheumatoid factor B cells after abortive activation by IgG. Proc. Natl. Acad. Sci. USA 94 (1997) 646-651
213. Till S.J., Francis J.N., Nouri-Aria K., and Durham S.R. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113 (2004) 1025-1034
214. Tschopp J.M., Sistek D., Schindler C., Leuenberger P., Perruchoud A.P., Wuthrich B., Brutsche M., Zellweger J.P., Karrer W., and Brandli O. Current allergic asthma and rhinitis: Diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy 53 (1998) 608-613
215. Tu Y., Salim S., Bourgeois J., Di Leo V., Irvine E.J., Marshall J.K., and Perdue M.H. CD23-mediated IgE transport across human intestinal epithelium: Inhibition by blocking sites of translation or binding. Gastroenterology 129 (2005) 928-940
216. van Cauwenberge P., Bachert C., Passalacqua G., Bousquet J., Canonica G.W., Durham S.R., Fokkens W.J., Howarth P.H., Lund V., Malling H.J., Mygind N., Passali D., et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55 (2000) 116-134
217. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., Fox H., and Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59 (2004) 709-717
218. Vigo P.G., Girgis K.R., Pfuetze B.L., Critchlow M.E., Fisher J., and Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J. Am. Acad. Dermatol. 55 (2006) 168-170
219. Walker K.Z., Boux H.A., Hayden G.E., Goodnow C.C., and Raison R.L. A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent. Adv. Exp. Med. Biol. 186 (1985) 833-841
220. Wan T., Beavil R.L., Fabiane S.M., Beavil A.J., Sohi M.K., Keown M., Young R.J., Henry A.J., Owens R.J., Gould H.J., and Sutton B.J. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat. Immunol. 3 (2002) 681-686
221. Warr G.W., Magor K.E., and Higgins D.A. IgY: Clues to the origins of modern antibodies. Immunol. Today 16 (1995) 392-398
222. Wasserman S.I. Mast cell-mediated inflammation in asthma. Ann. Allergy 63 (1989) 546-550
223. Watanabe N., Katakura K., Kobayashi A., Okumura K., and Ovary Z. Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis. Proc. Natl. Acad. Sci. USA 85 (1988) 4460-4462
224. Watanabe N., Ishiwata K., Kaneko S., Oku Y., Kamiya M., and Katakura K. Immune defense and eosinophilia in congenitally IgE-deficient SJA/9 mice infected with Angiostrongylus costaricensis. Parasitol. Res. 79 (1993) 431-434
225. Weimar W., Baumgartner D., Hendriks G.F., Hesse C.J., Balk A.H., Simoons M.L., and Bos E. The prophylactic use of Orthoclone OKT3 in kidney and heart transplantation. Transplant. Proc. 20 (1988) 96-100
226. Weiss M.E., Nyhan D., Peng Z.K., Horrow J.C., Lowenstein E., Hirshman C., and Adkinson Jr. N.F. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N. Engl. J. Med. 320 (1989) 886-892
227. Weissman D.N., and Lewis D.M. Allergic and latex-specific sensitization: Route, frequency, and amount of exposure that are required to initiate IgE production. J. Allergy Clin. Immunol. 110 (2002) S57-S63
228. Williams C.M., and Galli S.J. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 105 (2000) 847-859
229. Wilson D.R., Merrett T.G., Varga E.M., Smurthwaite L., Gould H.J., Kemp M., Hooper J., Till S.J., and Durham S.R. Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am. J. Respir. Crit. Care Med. 165 (2002) 22-26
230. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22 (2004) 1393-1398
231. Wurzburg B.A., Tarchevskaya S.S., and Jardetzky T.S. Structural changes in the lectin domain of CD23, the low-affinity IgE receptor, upon calcium binding. Structure 14 (2006) 1049-1058
232. Yamagata T., and Ichinose M. Agents against cytokine synthesis or receptors. Eur. J. Pharmacol. 533 (2006) 289-301
233. Zeiger R.S., and Heller S. Development of nasal basophilic cells and nasal eosinophils from age 4 months through 4 years in children of atopic parents. J. Allergy. Clin Immunol. 91 (1993) 723-734
234. Zheng Y., Shopes B., Holowka D., and Baird B. Conformations of IgE bound to its receptor Fc epsilon RI and in solution. Biochemistry 30 (1991) 9125-9132